Bao Y. Sciscent

Bao Y. Sciscent

Auto-generated profile, based on publicly available information

Bao Y. Sciscent

The Pennsylvania State University College of Medicine, Hershey, PA, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in OTO Open
Verified
Journal Article
Open access
BSBao Y. Sciscent
Bao Y. Sciscent
MPMarc Polanik
Marc Polanik
FLF. Jeffrey Lorenz
F. Jeffrey Lorenz
HEHänel W. Eberly
Hänel W. Eberly
MWMark E. Whitaker
Mark E. Whitaker
Objective: To investigate the prevalence of depression and anxiety in patients with vestibular disorders using a large patient database.Study Design: Retrospective cohort.Setting: The TriNetX database.Methods: TriNetX, a deidentified database, was retrospectively queried to identify adults with vestibular disorders. The rates of anxiety and depression in patients with vestibular disorders were compared to patients without vestibular disorders within 5 years of the index event, which was set at the time of diagnosis of vestibular dysfunction.Results: On analysis of patients with and without vestibular disorders, after propensity score matching for demographics and common comorbidities, 64,153 patients were identified in each cohort. Patients with vestibular disorders were more likely to have depression (relative risk [RR] 1.37 [95% CI 1.35‐1.40]) and anxiety (RR 1.51 [95% CI 1.45‐1.57]) compared to the general population. Similarly, a higher rate of antidepressant use was seen in patients with vestibular disorders (RR 1.41 [95% CI 1.39‐1.43]).Conclusion: Patients with vestibular disorders have higher rates of depression and anxiety compared to the general population.

8 January 2026 in OTO Open
Verified
Journal Article
Open access
BSBao Y. Sciscent
Bao Y. Sciscent
HEHanel W. Eberly
Hanel W. Eberly
FLF. Jeffrey Lorenz
F. Jeffrey Lorenz
DGDavid Goldrich
David Goldrich
NGNeerav Goyal
Neerav Goyal
DGDavid Goldenberg
David Goldenberg
Objective: Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) have shown remarkable results in glycemic control for patients with type 2 diabetes (T2DM). While no association has been made, there is a concern for thyroid cancer (TC) from GLP‐1RA. We aimed to study the 5‐year risk of TC in T2DM patients taking GLP‐1RA. Study Design: Retrospective cohort. Setting: TriNetX database. Methods: TriNetX was queried to identify T2DM patients between 2017 and 2019. The 5‐year risk of TC in patients using GLP‐1RA was compared to patients taking sodium‐glucose cotransporter 2 inhibitors (SGLT‐2I), metformin, and dipeptidyl peptidase 4 inhibitors (DPP‐4I) after propensity score matching by demographics and comorbidities. Results: On analysis of T2DM patients taking GLP‐1RA compared to SGLT‐2I, 7736 patients were in each cohort after matching. The 5‐year rate of TC in patients taking GLP‐1RA was 0.30% compared to 0.48% in those taking SGLT‐2I (RR 0.62 (95% CI 0.37‐1.05); P = .07). Analysis of GLP‐1RA versus metformin yielded 5158 patients in each cohort. Patients taking GLP‐1RA had similar rates of TC compared to those taking metformin (0.25% vs 0.39%; RR 0.65 (95% CI 0.32‐1.31); P = .22). A comparison of GLP‐1RA versus DPP‐4I yielded 12,570 patients in each cohort. The rate of TC was not increased in those taking GLP‐1RA compared to those taking DPP‐4I (0.33% vs 0.37%; RR 0.91 (0.60‐1.39); P = .67). Conclusion: T2DM patients taking GLP‐1RA may not have an increased 5‐year risk of TC compared to those taking metformin, SGLT‐2I, or DPP‐4I. Conclusions of long‐term use are limited as most GLP‐1RA were approved within the last decade.

30 March 2026 in Ear, Nose & Throat Journal
Verified
Journal Article
Open access
QDQuentin C. Durfee
Quentin C. Durfee
HEHänel W. Eberly
Hänel W. Eberly
BSBao Y. Sciscent
Bao Y. Sciscent
AMAndrew Meci
Andrew Meci
RCRachel Choi
Rachel Choi
VPVarun S. Patel
Varun S. Patel
Objective: YouTube is a video-sharing platform that patients frequently utilize. However, there are no objective assessments of the quality of information about otosclerosis on YouTube. Therefore, we aimed to assess the quality of YouTube videos for patient education via a cross-sectional study. We utilized 4 search phrases and analyzed them with 3 different scoring metrics, followed by statistical analysis. Results: Fifty videos were analyzed for the search terms “stapedectomy,” “stapedotomy,” “laser stapedotomy,” and “otosclerosis.” Most videos for “stapedotomy” (42%) and “otosclerosis” (41.2%) were intended for patients, while those for “stapedotomy” (48%) and “laser stapedotomy” (96%) were created for healthcare professionals or students. Higher modified DISCERN scores were associated with healthcare organization-produced videos for “otosclerosis” ( P = .01964) and “stapedotomy” ( P = .02842). Higher global quality score ( P = .02964) and Journal of the American Medical Society scores ( P = .01488) were significantly associated with videos made by verified users for “otosclerosis.” Conclusion: The quality of YouTube videos may not be sufficient for patient education on stapedectomy and stapedotomy for otosclerosis. Only 2 search terms included most videos geared toward patient education, while the other 2 terms had more videos for healthcare professionals. Lower transparency and reliability scores may give concerns about bias.

29 June 2026 in OTO Open
Verified
Journal Article
Open access
KCKimberly Chan
Kimberly Chan
CMCheng Ma
Cheng Ma
BSBao Y. Sciscent
Bao Y. Sciscent
AUAndreacarola Urso
Andreacarola Urso
NGNeerav Goyal
Neerav Goyal
JLJessyka G. Lighthall
Jessyka G. Lighthall
Objective: To systematically review the literature for medical therapies that promote facial nerve regeneration and recovery. Data Sources: PubMed/Medline, Embase, and SCOPUS databases were searched for English‐language studies published from inception through May 2025. Review Methods: Human studies evaluating the efficacy of medical therapy on facial nerve regeneration using validated facial nerve grading scales were included. Results: Nine studies were included in qualitative analysis, and 6 were included in a meta‐analysis. Treatments included nimodipine (n = 6), pentoxifylline (n = 1), co‐enzyme Q10 (n = 1), and extracellular vesicles (n = 1). All studies used HB score, and recovery was defined as HB score ≤3. Recovery was observed in 94% (95% CI:[90%, 97%]) of patients treated with nimodipine and 84% (95% CI: [70%, 97%]) of control patients; this was not statistically significant (OR 2.26, 95% CI: [0.97, 5.26]). Nimodipine significantly decreased HB score by 1.66 (95% CI: [0.81, 2.52]) before and after treatment. Pentoxifylline and extracellular vesicles demonstrated some efficacy, while co‐enzyme Q10 was not efficacious. Conclusion: Nimodipine improved HB score but was not significantly associated with recovery to HB score ≤3 compared to controls. Pentoxifylline and extracellular vesicles may have some efficacy, but co‐enzyme Q10 is not effective. Further research is required to uncover additional treatments.

26 January 2025 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Open access
MRMaxwell Rossip
Maxwell Rossip
FLF Jeffrey Lorenz
F Jeffrey Lorenz
BSBao Sciscent
Bao Sciscent
NTNguyen Truong
Nguyen Truong
CNChaitanya Nimmagadda
Chaitanya Nimmagadda
DGDavid Goldenberg
David Goldenberg
Objective: The objective of this study is to examine the risk of hypocalcemia after thyroidectomy in patients taking histamine‐2 receptor antagonists.Study Design: Retrospective cohort study.Setting: Multicenter, single database.Methods: Thirty‐four thousand two hundred eighteen patients treated with total thyroidectomy from 2011 to 2022 were identified via the TriNetX Research Network. We compared the incidence of transient (0‐1 month and 1‐6 months following thyroidectomy) and permanent (6‐12 months following thyroidectomy) postthyroidectomy hypocalcemia in patients with and without H2 receptor antagonists. Propensity score matching and sensitivity analysis were done to control for additional risk factors.Results: Patients were divided into 2 cohorts: those with an H2 receptor antagonist prescription before surgery (n = 5108) and those without (n = 29,110). 44.9% and 11.6% of thyroidectomy patients taking H2 receptor antagonists had hypocalcemia compared to 38.3% and 8.2% of patients without H2 receptor antagonists at 0 to 1 month and 6 to 12 months, respectively. Patients taking H2 receptor antagonists had a significantly increased risk of experiencing hypocalcemia at 0 to 1 month, 1 to 6 months, and 6 to 12 months. Patients taking H2 receptor antagonists were also at increased risk for visiting the emergency department and receiving intravenous calcium replenishment at 1 and 6 months following surgery. Sensitivity analysis continued to yield significant results at all time points.Conclusion: Patients taking H2 receptor antagonists may be at increased risk of short and long‐term hypocalcemia after thyroid surgery. This is the first retrospective cohort study examining the risk of hypocalcemia after thyroidectomy in patients taking H2 receptor antagonists.